OCULAR DRUG DELIVERY SYSTEMS: AN OVERVIEW
Abstract
The treatment for the ophthalmic diseases are topical route because of the various ocular barrier. Ocular drug delivery systems are considered as major challenges by today’s pharmacologist and formulation scientist. Topical eye drop is the most convenient and patient compliant route of drug administration, especially for the treatment of anterior segment diseases. tissues. In the past two decades, ocular drug delivery research acceleratedly advanced towards developing a novel, safe and patient compliant formulation and drug delivery techniques, which may surpass these barriers and maintain drug levels in tissues. There are many eye ailments which affected to eye and one can loss the eye sight also. Therefore, many ophthalmic drug delivery systems are available. These are classified as conventional and non- conventional (newer) drug delivery systems. Most commonly available ophthalmic preparations are eye drops and ointments about 70% of the eye dosage formulations in market. So overcome to these problems newer pharmaceutical ophthalmic formulation such as in-situ gel, nanoparticle, liposome, nanosuspension, microemulsion, intophoresis and ocular inserts have been developed in last three decades increase the bioavailability of the drug as a sustained and controlled manner.
Downloads
References
Mitra AK: Ophthalmic Drug Delivery Systems, 2003; 704.
Reddu IK: Ocular therapeutics and drug delivery: CRC Press, 1995.
Saettone MF: Progress and Problems in Ophthalmic Drug Delivery. Business Briefing: Pharmatech. 2002:167-171.
Qi H, Wenwen C, Chunyan H, Li L, Chuming C, Wenmin L and Chunjie W: Development of a poloxamer analogs/carbopol-based in situ gelling and Mucoadhesive ophthalmic delivery system for puerarin. Int. J. Pharm. 2007; 337:178– 187.
Valerie CS, Tina S, Essentials of anatomy and physiology, 5th edition,1999:201
Karesh, JW: Topographic anatomy of the eye. Foundations of Clinical Ophthalmology, 2003; 1: 1-16.
Smolek MK and Klyce SD: Cornea of Clinical Ophthalmology, 2003; 1: 1-10.
De la Maza MS and Foster CS : Sclera. Foundations of Clinical Ophthalmology, vol. 1, eds. W. Tasman and E.A. Jaeger. Philadelphia: Lippincott Williams & Wilkins, chap. 1.
Buggage RR, Torczynski E and Grossniklaus HE: Choroid and suprachoroid.Foundations of Clinical Ophthalmology 2003; 1: 1-10.
Park SS, Sigelman J and Gragoudas ES: The anatomy and cell biology of the retina. Foundations of Clinical Ophthalmology, 2002; 1: 1-10.
Reddy KR, Yadav MR, Reddy PS. Preparation and evaluation of aceclofenac ophthalmic in-situ gels. J Chem Biol Phys Sci 2011;1:289-98.
Champalal KD, Sushilkumar P. Current status of ophthalmic insitu forming hydrogel. Int J Pharm Bio Sci 2012;3:372-88.
Burgalassi S, Chetoni P, Monti D, Saettone MF. Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines. Toxicol Lett 2001;122:1-8.
Ramesh Y, Kothapalli CB, Reddigari JR. A novel approaches on ocular drug delivery system. J Drug Delivery Ther 2017;7:117-24.
Patel PB, Shastri PK, Sehlat PK, Shukla AK. Opthalmic drug delivery systems: challenges and approaches. Systemic Rev Pharm 2010;1:113-20.
Peyman GA, Ganiban GJ. Delivery systems for intraocular routes. Adv Drug Delivery Rev 1995;16:107-23.
Janoria KG, Gunda S, Boddu SH, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Delivery 2007;4:371-88.
Duvvuri S, Majumdar S, Mitra AK. Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther 2003;3:45-56.
Lambert G, Guilatt RL. Current ocular drug delivery challenges. Drug Dev Report Industry Overview Deals 2005;33:1-2.
Lang JC. Ocular drug delivery conventional ocular formulations. Adv Drug Delivery Rev 1995;16:39-43.
Saettone MF, Giannaccini B, Ravecca S, La Marca F, Tota G. Polymer effects on ocular bioavailability-the influence of different liquid vehicles on the mydriatic response of
tropicamide in humans and in rabbits. Int J Pharm 1984;20:187-202.
Saettone MF, Giannaccini B, Ravecca S, LaMarca F, Tota G. Evaluation of viscous ophthalmic vehicles containing carbomer by slit-lamp fluorophotometry in humans. Int J Pharm 1984;20:187-202.
Copyright (c) 2022 IJRDO-Journal of Applied Science
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Author(s) and co-author(s) jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere. Author(s) agree to the terms that the IJRDO Journal will have the full right to remove the published article on any misconduct found in the published article.
